From: Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)
Variable
Beta coefficient ± standard error
p value
Constant
14.4 ± 2.6
< 0.001
BMI < 25 kg/m2
7.6 ± 3.6
0.036
Mixed hyperlipidemia
0.82 ± 0.2
0.003
Percent of change of triglycerides
0.68 ± 0.4